Abbott Dx Revenues Rise 4 Percent in Q2 on Strong Core Lab and Point-of-Care Growth

Jul 20, 2017

|

This article has been updated to include additional comments from Abbott's earnings call.

NEW YORK (GenomeWeb) – Abbott today said that its Diagnostics business grew sales 4 percent year over year in the second quarter, driven in part by strong growth in for its core laboratory and point-of-care tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Abbott Dx Revenues Rise 4 Percent in Q2 on Strong Core Lab and Point-of-Care Growth

To read the full story....

Breaking News

CMS Releases New Guidance Requiring Payors to Cover COVID-19 Testing Without Cost Sharing

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval

360Dx Index Declines 4 Percent in February, Ending Streak of Gains

What's Popular?

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

Luminex Shares Surge on Rumor of Acquisition by DiaSorin

Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Adaptive Biotechnologies Touts New Era of T Cell-Based Dx With T-Detect COVID Launch

Sponsorships